Revance Therapeutics to Release Third Quarter 2016 Financial Results Thursday, November 3, 2016
October 24 2016 - 4:05PM
Business Wire
- Conference Call Scheduled for Thursday,
November 3, 2016 at 4:30pm ET -
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing botulinum toxin products for use in aesthetic
and therapeutic indications, today announced that the company will
release third quarter 2016 financial results on Thursday, November
3, 2016 after the close of market. Revance will host a
corresponding conference call and a live webcast at 1:30pm
PT/4:30pm ET on the same day to discuss the results and
provide a business and pipeline update.
Individuals interested in listening to the conference call may
do so by dialing (855) 453-3827 for domestic callers, or (484)
756-4301 for international callers and reference conference ID:
96279951; or from the webcast link in the investor relations
section of the company's website at: www.revance.com.
A replay of the call will be available beginning November
3, 2016 at 5:00pm PT/8:00pm ET to November 4,
2016 at 5:00pm PT/8:00pm ET. To access the replay, dial (855)
859-2056 or (404) 537-3406 and reference conference ID: 96279951.
The webcast will be available in the investor relations section on
the company's website for 30 days following the completion of the
call.
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is
committed to the advancement of remarkable science. The company is
developing a portfolio of products for aesthetic medicine and
underserved therapeutic specialties, including dermatology and
neurology. Revance's science is based upon a proprietary TransMTS®
peptide technology, which when combined with active drug molecules,
may help address current unmet needs.
Revance's initial focus is on developing daxibotulinumtoxinA,
the company's highly purified botulinum toxin, for a broad spectrum
of aesthetic and therapeutic indications, including facial wrinkles
and muscle movement disorders. The company's lead drug candidate,
DaxibotulinumtoxinA for Injection (RT002), is currently in
development for the treatment of glabellar lines and cervical
dystonia and has the potential to be the first long-acting
neurotoxin. The company holds worldwide rights for all indications
of RT002 injectable and RT001 topical and the pharmaceutical uses
of the TransMTS technology platform. More information on Revance
may be found at www.revance.com.
"Revance Therapeutics", TransMTS®, “Remarkable Science Changes
Everything”, and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161024005850/en/
Investors:Revance TherapeuticsJeanie Herbert, (714)
325-3584jherbert@revance.comorBurns McClellanAmi Bavishi, (212)
213-0006abavishi@burnsmc.comorTrade Media:Nadine Tosk, (504)
453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024